JP2007501793A5 - - Google Patents

Download PDF

Info

Publication number
JP2007501793A5
JP2007501793A5 JP2006522744A JP2006522744A JP2007501793A5 JP 2007501793 A5 JP2007501793 A5 JP 2007501793A5 JP 2006522744 A JP2006522744 A JP 2006522744A JP 2006522744 A JP2006522744 A JP 2006522744A JP 2007501793 A5 JP2007501793 A5 JP 2007501793A5
Authority
JP
Japan
Prior art keywords
composition
hydrogen
methyl
och
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006522744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501793A (ja
JP4741491B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/025409 external-priority patent/WO2005013996A2/en
Publication of JP2007501793A publication Critical patent/JP2007501793A/ja
Publication of JP2007501793A5 publication Critical patent/JP2007501793A5/ja
Application granted granted Critical
Publication of JP4741491B2 publication Critical patent/JP4741491B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006522744A 2003-08-07 2004-08-06 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用 Expired - Fee Related JP4741491B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49400803P 2003-08-07 2003-08-07
US60/494,008 2003-08-07
US57253404P 2004-05-18 2004-05-18
US60/572,534 2004-05-18
PCT/US2004/025409 WO2005013996A2 (en) 2003-08-07 2004-08-06 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

Publications (3)

Publication Number Publication Date
JP2007501793A JP2007501793A (ja) 2007-02-01
JP2007501793A5 true JP2007501793A5 (enrdf_load_stackoverflow) 2007-09-20
JP4741491B2 JP4741491B2 (ja) 2011-08-03

Family

ID=34138795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522744A Expired - Fee Related JP4741491B2 (ja) 2003-08-07 2004-08-06 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用

Country Status (9)

Country Link
US (6) US20050113398A1 (enrdf_load_stackoverflow)
EP (1) EP1663242B1 (enrdf_load_stackoverflow)
JP (1) JP4741491B2 (enrdf_load_stackoverflow)
AT (1) ATE506953T1 (enrdf_load_stackoverflow)
DE (1) DE602004032446D1 (enrdf_load_stackoverflow)
DK (1) DK1663242T3 (enrdf_load_stackoverflow)
ES (1) ES2365223T3 (enrdf_load_stackoverflow)
SI (1) SI1663242T1 (enrdf_load_stackoverflow)
WO (1) WO2005013996A2 (enrdf_load_stackoverflow)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
SG176311A1 (en) * 2002-07-29 2011-12-29 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2533377C (en) * 2003-07-30 2012-11-27 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
SI1663242T1 (sl) * 2003-08-07 2011-09-30 Rigel Pharmaceuticals Inc 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
DK1660458T3 (da) * 2003-08-15 2012-05-07 Irm Llc 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
DK1814878T3 (da) * 2004-11-24 2012-05-07 Rigel Pharmaceuticals Inc Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
ES2545382T3 (es) 2005-04-28 2015-09-10 Mitsubishi Tanabe Pharma Corporation Derivado de cianopiridina y su uso como medicamento
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
DE102005027274A1 (de) * 2005-06-08 2006-12-14 Schering Ag Inhibitoren der löslichen Adenylatzyklase
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7417066B2 (en) 2005-06-08 2008-08-26 Schering Ag Inhibitors of soluble adenylate cyclase
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
DE602005000514T2 (de) * 2005-06-17 2007-10-25 Magneti Marelli Powertrain S.P.A. Brennstoffeinspritzventil
EA200800285A1 (ru) * 2005-07-11 2008-08-29 Санофи-Авентис Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
FR2888239B1 (fr) * 2005-07-11 2008-05-09 Sanofi Aventis Sa Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US8372851B2 (en) 2005-10-21 2013-02-12 Exelixis, Inc. Pyrazolo pyrimidines as casein kinase II (CK2) modulators
JP4653842B2 (ja) * 2006-02-17 2011-03-16 ライジェル ファーマシューティカルズ， インコーポレイテッド 自己免疫疾患を治療または予防するための２，４−ピリミジンジアミン化合物
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
PE20120006A1 (es) * 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
KR20090019011A (ko) 2006-06-15 2009-02-24 베링거 인겔하임 인터내셔날 게엠베하 단백질 키나아제 ｃ-알파의 억제제로서의 2-아닐리노-4-(헤테로사이클릭)아미노-피리미딘
MX2008016007A (es) 2006-06-15 2009-01-16 Boehringer Ingelheim Int 2-anilino-4-aminoalquilenoaminopirimidinas.
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
TWI432427B (zh) 2006-10-23 2014-04-01 Cephalon Inc 作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物
WO2008061201A1 (en) * 2006-11-15 2008-05-22 Rigel Pharmaceuticals, Inc. Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
GEP20156282B (en) 2006-12-08 2015-05-11 Irm Llc Compounds and compositions as protein kinase inhibitors
US20100144732A1 (en) * 2006-12-19 2010-06-10 Krueger Elaine B Pyrimidine kinase inhibitors
JP2010513406A (ja) * 2006-12-22 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療のための細胞周期キナーゼ阻害剤としての２−［（フェニルアミノ）−ピリミジン−４−イルアミノ］−シクロペンタンカルボキサミド誘導体及び関連化合物
CA2673307A1 (en) 2006-12-22 2008-07-03 F. Hoffman-La Roche Ag Spiro-piperidine derivatives
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2134684B1 (en) 2007-04-16 2017-08-02 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2009012421A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
RU2010132728A (ru) 2008-01-11 2012-02-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
WO2009103652A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US20100155402A1 (en) * 2008-02-27 2010-06-24 Pwp Industries, Inc. Display and storage container
AU2009233964B2 (en) 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CN102203083A (zh) * 2008-06-25 2011-09-28 Irm责任有限公司 作为激酶抑制剂的嘧啶衍生物
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
CN102137847B (zh) 2008-07-01 2015-06-10 健泰科生物技术公司 作为mek激酶抑制剂的二环杂环
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
CA2743196A1 (en) 2008-11-10 2010-05-14 F.Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
CA2747326C (en) 2008-12-22 2017-05-16 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
WO2010078369A2 (en) * 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
WO2010083240A2 (en) * 2009-01-14 2010-07-22 Rigel Pharmaceuticals, Inc. Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
US8394951B2 (en) * 2009-01-15 2013-03-12 Rigel Pharmaceuticals Inc. Protein kinase C inhibitors and uses thereof
JP5781943B2 (ja) * 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
CN102470135A (zh) * 2009-07-28 2012-05-23 里格尔药品股份有限公司 抑制jak途径的组合物和方法
CN102002121A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 树脂，抗蚀剂组合物和用于制造抗蚀剂图案的方法
US8389515B2 (en) 2009-11-20 2013-03-05 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs and their uses
EP2507227B1 (en) 2009-12-01 2014-10-08 Rigel Pharmaceuticals, Inc. Tetrazolones as protein kinase c inhibitors and uses thereof
US8486096B2 (en) * 2010-02-11 2013-07-16 Ethicon Endo-Surgery, Inc. Dual purpose surgical instrument for cutting and coagulating tissue
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
EP2558474B1 (en) 2010-04-13 2015-11-25 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
EP2395001A1 (en) * 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
EP2571867B1 (en) 2010-05-21 2015-11-04 Noviga Research AB Novel pyrimidine derivatives
HRP20160771T1 (hr) 2010-06-04 2016-09-23 F. Hoffmann - La Roche Ag Derivati aminopirimidina kao modulatori za lrrk2
JP6035238B2 (ja) * 2010-07-21 2016-11-30 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
US9063414B2 (en) 2010-07-28 2015-06-23 Sumitomo Chemical Company, Limited Photoresist composition
KR20130099040A (ko) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Ｂｔｋ 억제제의 베실레이트 염
TWI521302B (zh) 2010-08-30 2016-02-11 住友化學股份有限公司 阻劑組成物及阻劑圖案的產生方法
MY181898A (en) 2010-11-01 2021-01-12 Celgene Car Llc Heterocyclic compounds and uses thereof
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
RS59106B1 (sr) 2010-11-10 2019-09-30 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
JP5947053B2 (ja) 2011-02-25 2016-07-06 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5947051B2 (ja) 2011-02-25 2016-07-06 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5829939B2 (ja) 2011-02-25 2015-12-09 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5898520B2 (ja) 2011-02-25 2016-04-06 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5829941B2 (ja) 2011-02-25 2015-12-09 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5829940B2 (ja) 2011-02-25 2015-12-09 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP6034026B2 (ja) 2011-02-25 2016-11-30 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5898521B2 (ja) 2011-02-25 2016-04-06 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP6034025B2 (ja) 2011-02-25 2016-11-30 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2012154518A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
MX2013013090A (es) 2011-05-10 2013-12-16 Merck Sharp & Dohme Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
JP5912912B2 (ja) 2011-07-19 2016-04-27 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP5886696B2 (ja) 2011-07-19 2016-03-16 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP6189020B2 (ja) 2011-07-19 2017-08-30 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP6013797B2 (ja) 2011-07-19 2016-10-25 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
JP6013799B2 (ja) 2011-07-19 2016-10-25 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
ES2710423T5 (en) 2011-07-28 2025-02-13 Rigel Pharmaceuticals Inc New (trimethoxyphenylamino)pyrimidinyl formulations
JP2014524456A (ja) 2011-08-25 2014-09-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン／スレオニンｐａｋ１阻害剤
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
EP2794605A1 (en) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag 2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
BR112014022790B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
CA2900012A1 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
CN105017159B (zh) * 2014-04-28 2019-05-17 四川大学 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途
WO2016022460A1 (en) 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
US11203576B2 (en) * 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
FI3555070T3 (fi) * 2016-12-19 2023-09-12 Epizyme Inc Amiini-substituoituja, heterosyklisiä yhdisteitä ehmt2:n estäjinä ja niiden käyttömenetelmiä
RU2019128534A (ru) 2017-02-15 2021-03-16 Наньян Текнолоджикал Юниверсити Химические соединения для лечения туберкулеза
AU2018254577B2 (en) 2017-04-21 2024-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
JP7254076B2 (ja) * 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
SI3966206T1 (sl) 2019-05-10 2023-12-29 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidinski amidni zaviralci avtofagije in načini njihove uporabe
TWI865526B (zh) 2019-05-10 2024-12-11 美商迪賽孚爾製藥有限公司 苯基胺基嘧啶醯胺自噬抑制劑及其使用方法
US11590134B2 (en) 2019-06-17 2023-02-28 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN115141150B (zh) * 2022-07-25 2024-04-26 南通大学 2,4,5-三取代嘧啶羟胺酰衍生物及其制备方法与应用
CN115304551A (zh) * 2022-07-25 2022-11-08 南通大学 2-((4-吗啉苯基)氨基)嘧啶氨基酸衍生物及其制备方法与应用
CN115232076A (zh) * 2022-07-25 2022-10-25 南通大学 苯氨基取代的嘧啶氨基酸衍生物及其制备方法与应用
CN115304550A (zh) * 2022-07-25 2022-11-08 南通大学 哌嗪苯基氨基取代的嘧啶氨基酸衍生物及制备方法与应用
CN119431398A (zh) * 2023-07-31 2025-02-14 中国科学院上海有机化学研究所 R406及其衍生物协同trail的抗肿瘤应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
PT96059B (pt) 1989-12-04 1998-07-31 Searle & Co Sistema de camada unica para a administracao de um medicamento por via transdermica
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE60138645D1 (de) * 2000-12-21 2009-06-18 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
MEP13408A (en) * 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
AU2002367172A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
SG176311A1 (en) * 2002-07-29 2011-12-29 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
JP4634367B2 (ja) * 2003-02-20 2011-02-16 スミスクライン ビーチャム コーポレーション ピリミジン化合物
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2533377C (en) * 2003-07-30 2012-11-27 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
SI1663242T1 (sl) * 2003-08-07 2011-09-30 Rigel Pharmaceuticals Inc 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20060051406A1 (en) * 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2008061201A1 (en) * 2006-11-15 2008-05-22 Rigel Pharmaceuticals, Inc. Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
JP5781943B2 (ja) * 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体
EP2507227B1 (en) * 2009-12-01 2014-10-08 Rigel Pharmaceuticals, Inc. Tetrazolones as protein kinase c inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2007501793A5 (enrdf_load_stackoverflow)
RU2468021C2 (ru) Гетероциклические соединения и их применение
JP2012505871A5 (enrdf_load_stackoverflow)
JP2020524719A5 (enrdf_load_stackoverflow)
JP2007511504A5 (enrdf_load_stackoverflow)
JP2019518766A5 (enrdf_load_stackoverflow)
JP2017537080A5 (enrdf_load_stackoverflow)
JP2014534200A5 (enrdf_load_stackoverflow)
RU2018103907A (ru) Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
JP2008533191A5 (enrdf_load_stackoverflow)
JP2014520898A5 (enrdf_load_stackoverflow)
RU2000127751A (ru) Противоопухолевое средство
CA2518115A1 (en) Nucleotide phosphoramidates as anticancer agents
JP2011517443A5 (enrdf_load_stackoverflow)
JP2019529518A5 (enrdf_load_stackoverflow)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2004524340A5 (enrdf_load_stackoverflow)
JP2017511321A5 (enrdf_load_stackoverflow)
JP2015522551A5 (enrdf_load_stackoverflow)
RU2019110048A (ru) Твердые формы валбеназина
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
RU2012103460A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ИМИДАЗО{1,2-a}ПИРИМИДИН-5-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ФАРМАЦИИ
RU2007116987A (ru) Новые соединения
JP2015502371A5 (enrdf_load_stackoverflow)
JP2010535706A5 (enrdf_load_stackoverflow)